Screening for synchronous metastases in colorectal cancer with DW-MRI (SERENADE)

SERENADE is a phase II multicentre, interventional study, which aims to establish whether additional staging with liver diffusion-weighted MRI diagnoses more synchronous metastases than CT alone when colorectal cancer is diagnosed.

The accurate and timely diagnosis of metastatic disease is crucial to enable early surgical referral for metastectomy and neoadjuvant treatment. Contrast enhanced CT is the standard imaging modality for the diagnosis of liver metastases, but MRI with liver specific contrast and diffusion weighted imaging (DW-MRI) is regarded as the gold standard for the di-agnosis of liver metastases DW-MRI is quick and as it does not require contrast agents has no significant additional costs, with the standard sequences taking approximately 10 minutes to compete.

The primary objective of this study is will be to show a >5% increase in the incidence of synchronous liver metastases additionally diagnosed by hepatic diffusion weighted MRI when CT is negative or does not confirm the presence of metastatic disease in patients with high risk colorectal cancer—T3c/d, mrEMVI positive.

The SERENADE trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.